U.S., Nov. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07249892) titled 'A Study of BPR-6023021 in Advanced Solid Tumors With Bone Metastases' on Nov. 14.
Brief Summary: A multicenter, open-label Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, dosimetry and efficacy of BPR-6023021 in subjects with advanced solid tumors with bone metastases
Study Start Date: Nov. 19
Study Type: INTERVENTIONAL
Condition:
Metastatic Solid Tumors
Intervention:
DRUG: BPR-6023021 for injection
BPR-6023021 is a Radionuclide conjugated drugs (RDC) targeting bone.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Chengdu Syncor Pharmaceutical Co., Ltd.
Disclaimer: Curated by HT Syndication....